Thermo Fisher Scientific UFD1L Polyclonal Antibody

Applications

Western Blot (WB)

• Tested Dilution: 1:500–1:2,000

Immunocytochemistry (ICC/IF)

• Tested Dilution: 1:50–1:200

Product Specifications

Product Specific Information

• Purity is >95% by SDS-PAGE.

Target Information

Ubiquitin-mediated proteolysis requires the transfer of ubiquitin (Ub) to lysine groups on selected cellular proteins, which then potentiates the proteolytic degradation of these protein conjugates by the 26S proteasome. Ub-fusions are cleaved by Ub-specific processing proteases (UBps) or alternatively by the Ub-fusion degradation (UFD) pathway.
The UBP pathway targets the C-terminal glycine residue on Ub that is involved in the formation of Ub-conjugates, while UFD proteins preferentially cleave Ub-conjugated proteins that contain an amino acid substitution at this glycine residue.
The UFD1 protein was originally characterized in yeast S. cerevisiae and subsequently, the human homolog UFD1 or UFD1L was identified. In vitro, UFD1 attenuates the degradation of Ub-fusions with proline or valine substitution at Gly76 by selective multiubiquitination of the Ub chain of the Ub-conjugate.
Mutations within the UFD1 gene are implicated in the development of CATCH22 syndrome, characterized by cardiac defects, cleft palate, and hypocalcemia, suggesting that this proteolytic pathway may be involved in these developmental defects.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.